Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients

被引：1
|
作者：
Gorgulho, Joao [1 ]
von Felden, Johann [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Gastroenterol & Hepatol, Hamburg, Germany
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期
关键词：
D O I：
10.1111/apt.18296
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1467 / 1468
页数：2
相关论文
共 50 条
  • [1] Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishikawa, Hiroki
    Nishimura, Takashi
    Kawata, Kazuhito
    Kosaka, Hisashi
    Naganuma, Atsushi
    Yata, Yutaka
    Ohama, Hideko
    Kuroda, Hidekatsu
    Matono, Tomomitsu
    Aoki, Tomoko
    Kanayama, Yuki
    Tanaka, Kazunari
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Nakamura, Shinichiro
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1361 - 1373
  • [2] Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Authors' Reply
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kumada, Takashi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1469 - 1470
  • [3] Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab
    Kikuchi, Tatsuya
    Takeuchi, Yasuto
    Nouso, Kazuhiro
    Kariyama, Kazuya
    Kuwaki, Kenji
    Toshimori, Junichi
    Iwado, Shota
    Moriya, Akio
    Hagihara, Hiroaki
    Takabatake, Hiroyuki
    Tada, Toshifumi
    Yasunaka, Tetsuya
    Sakata, Masahiro
    Sue, Masahiko
    Miyake, Nozomi
    Adachi, Takuya
    Wada, Nozomu
    Onishi, Hideki
    Shiraha, Hidenori
    Takaki, Akinobu
    Otsuka, Motoyuki
    LIVER INTERNATIONAL, 2024, 44 (06) : 1456 - 1463
  • [4] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Tahata, Yuki
    Imai, Yasuharu
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Mita, Eiji
    Ito, Toshifumi
    Hagiwara, Hideki
    Yakushijin, Takayuki
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307
  • [5] The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
    Shimose, Shigeo
    Saeki, Issei
    Ito, Takanori
    Takeuchi, Yasuto
    Tani, Joji
    Tomonari, Tetsu
    Sasaki, Ryu
    Sasaki, Kyo
    Kakizaki, Satoru
    Hatanaka, Takeshi
    Iwamoto, Hideki
    Tanabe, Norikazu
    Yamamoto, Takafumi
    Naganuma, Atsushi
    Shirono, Tomotake
    Kanayama, Yuki
    Nishina, Sohji
    Takayama, Tetsuji
    Kobara, Hideki
    Otsuka, Motoyuki
    Kawashima, Hiroki
    Takami, Taro
    Kawaguchi, Takumi
    Hepatology InVestigator Experts Japan HIVE-J Study Grp
    HEPATOLOGY INTERNATIONAL, 2025,
  • [6] Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
    Wu, Jun-Yi
    Zeng, Zhen-Xin
    Li, Yi-Nan
    Zhang, Zhi-Bo
    Zhuang, Shao-Wu
    Li, Bin
    Zhou, Jian-Yin
    Li, Shu-Qun
    Liu, De-Yi
    Li, Han
    Ou, Xiang-Ye
    Wu, Jia-Yi
    Yan, Mao-Lin
    LIVER CANCER, 2025,
  • [7] Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
    Matsuoka, Taisuke
    Fujikawa, Takahisa
    Uemoto, Yusuke
    Aibe, Yuki
    Hasegawa, Suguru
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [8] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
    Chon, Young Eun
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Hong Jae
    Kim, Beom Kyung
    CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
  • [9] α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
    Rossari, Federico
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Yoo, Changhoon
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Bergamo, Francesca
    Amadeo, Elisabeth
    Vitiello, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Iavarone, Massimo
    Cabibbo, Giuseppe
    Montes, Margarida
    Foschi, Francesco Giuseppe
    Vivaldi, Caterina
    Solda, Caterina
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Hiraoka, Atsushi
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (06) : 1043 - 1056
  • [10] Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab"
    Kikuchi, Tatsuya
    Takeuchi, Yasuto
    Nouso, Kazuhiro
    Kariyama, Kazuya
    Kuwaki, Kenji
    Toshimori, Junichi
    Iwado, Shota
    Moriya, Akio
    Hagihara, Hiroaki
    Takabatake, Hiroyuki
    Tada, Toshifumi
    Yasunaka, Tetsuya
    Sakata, Masahiro
    Sue, Masahiko
    Miyake, Nozomi
    Adachi, Takuya
    Wada, Nozomu
    Onishi, Hideki
    Shiraha, Hidenori
    Takaki, Akinobu
    Otsuka, Motoyuki
    LIVER INTERNATIONAL, 2024, 44 (07) : 1736 - 1737
12345